Best Polycythemia Vera Podcasts (2024)

1
Episode 48. Management of Polycythemia Vera with Dr. Aaron Gerds 57:09

1h ago57:09

57:09

In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed: 1. MIPS PV scoring system https://pubmed.ncbi.nlm.nih.gov/31945802/ 2. REVEAL study https://ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell…

1
What to Know about Progression in Polycythemia Vera 23:43

11d ago23:43

23:43

On this episode, Dr. Douglas Tremblay from Mount Sinai School of Medicine in New York City discusses progression in polycythemia vera (PV). He elaborates on the transformation of PV into other diseases such as myelofibrosis and acute myeloid leukemia (AML), different ways progression can be defined, and the factors that contribute to the risk of pr…

1
The Dark Side of High Achievement 38:27

9m ago38:27

38:27

Is there a darker side to the extraordinary accomplishments of people with bleeding disorders? Guest segment host, Luke Pembroke, ask just that on the latest I’m Fine, featuring blood brother and Paralympian, Jack Bridge. Also, Patrick and Amy hit up the Chief Patient Officer Summit and got insight on what true patient inclusivity is all about. Plu…

1
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs 34:45

2h ago34:45

34:45

In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer. Presenters: Virginia Kaklamani, MD, DSc Prof…

1
Current Clinical Practice and NCCN Guidelines for CLL/SLL 31:33

3h ago31:33

31:33

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including: Prognostic variables when deciding between regimens Role of MRD in CLL Results from the phase II CAPTIVATE trial Choosing among th…

1
Clinical Trials, Caregiving, and NEW MUSIC!? 43:37

1d ago43:37

43:37

On this episode, Patrick James Lynch honors the late Neil Frick, Senior VP for Medical Programs at the National Bleeding Disorders Foundation, recognizing his invaluable two-decade contribution to the bleeding disorders community. We also discuss hemophilia B gene therapy with Dr. Mark Redding, focusing on unique clinical trial designs and the role…

1
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs 28:35

1d ago28:35

28:35

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including: Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the M…

1
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways 24:23

2d ago24:23

24:23

In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including: Rationale for targeting CELMoDs in NHL Mechanism of action of CELMoDs Key studies and available efficacy and safety data with investigational CELMoDs in NHL Key ongoing clinical trials of CELMoDs in NHL Strategies to…

1
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer 24:30

4d ago24:30

24:30

In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemacicli…

1
Congress to Clinic: Expert Takeaways on Emerging Data for AML 25:21

5d ago25:21

25:21

In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractor…

1
Episode 47. ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni 47:48

7d ago47:48

47:48

In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL https://library…

1
Congress to Clinic: Expert Takeaways on Emerging Data for MDS 19:19

8d ago19:19

19:19

In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low…

1
The multi-faceted role of HTC social workers 1:02:23

15d ago1:02:23

1:02:23

Patrick sits down with HTC social workers, Kathaleen Schnur and Dianne Bartlett, about the ever-evolving role of social workers in the HTC comprehensive care system. Plus, on the latest I’m Fine, Patrick answers the question, What do clotting factor levels mean to me in this new age of hemophilia treatment? Show Notes: Subscribe: The BloodStream Po…

1
Life with an Invisible Disorder 28:15

29d ago28:15

28:15

Patrick sits down with Thomas Bartlett, Myasthenia Gravis patient and advocate, about the unique struggles of living with an invisible chronic disorder. Also, we all know if you want real answers — ask a nurse. We’ve got Andrea Buxton, Nurse Practitioner at the Hemophilia Outreach Center in Green Bay, WI, with her account of the first commercial do…

1
Episode 46. Updates in Myeloma MRD with Dr. Ben Derman and Dr. Manni Mohyuddin 57:48

1M ago57:48

57:48

In this episode, we dive into updates in Minimal Residual Disease (MRD) in multiple myeloma, along with the FDA ODAC meeting in April 2024 to decide on MRD as a surrogate endpoint for accelerated approval. Our guests are Dr. Benjamin Derman and Dr. Manni Mohyuddin. Here are the key papers we discussed: 1. Recording of FDA ODAC meeting: https://www.…

1
Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi 1:00:53

2M ago1:00:53

1:00:53

In this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic. The key studies and trials discussed are as follows: · GIPSS: Genetically inspired prognostic scoring system that is exclusively based on genetic markers. § https://www.nature.com/articles/s41375-018-0107-z · MIPSS70+ Version 2.0: Mutation and…

1
Polycythemia Rubra Vera 1:12:33

2M ago1:12:33

1:12:33

Polycythaemia- red cell # Erythrocytosis – in red cell mass Absolute Erythrocytosis - M: Hct >0.60 or >0.52 + RCM >25% of mean - F: Hct >0.56 or >0.48 + RCM >25% of mean Apparent Erythrocytosis - Men: Hct >0.52 + normal RCM - Women: Hct >0.48 + normal RCM Relative erythrocytosis -Normal RCM + Reduced plasma volume (pathological dehydration) M>F Med…

1
Mild Hemophilia Matters 56:20

2M ago56:20

56:20

Mild hemophilia truly does matter and we’re with Shellye Horowitz, formally with HFA, to hear about HFA’s Mild Matters program. Plus the final Elite Athletes segment with Paul McLaughlin and I’m Fine with Luke Pembroke. Show Notes: Subscribe: The BloodStream Podcast Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more. I’m Fine and…

1
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer 25:55

2M ago25:55

25:55

In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast canc…

1
Secondary CNS Lymphoma 37:30

3M ago37:30

37:30

- Synchronous CNS and systemic lymphoma at initial presentation (treatment-naïve; TN-SCNSL) - CNS relapse without recurrent systemic lymphoma (relapsed isolated CNS lymphoma; RI-SCNSL) - Relapsed concomitant systemic and CNS disease following treatment for systemic lymphoma (RC-SCNSL) Generally hybrid disease Investigations - MRI Head w gadolinium …

1
UK Blood Inquiry Clive Smith & Laurence Woollard 52:26

2M ago52:26

52:26

Our blood brother buds, Clive Smith & Laurence Woollard join us today to share the latest from the ongoing saga of UK Blood Inquiry, plus our latest Gene Therapy segment has Mason Buxton’s story (the first hemophilia B patient to be commercially dosed with gene therapy!). Show Notes: Subscribe: The BloodStream Podcast Presenting Sponsor: Takeda, vi…

1
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 47:23

2M ago47:23

47:23

In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, includin…

1
Navigating the Currents: Interferons in the Treatment of Polycythemia Vera 25:45

2M ago25:45

25:45

On this special episode of the BloodStream Podcast, we explore interferons in the treatment of polycythemia vera (or PV). This episode is brought to you by PharmaEssentia. If you’d like to learn more about polycythemia vera, check out our sister show PV Pod: Stories from the Marrow (brought to you by BloodStream Media and PharmaEssentia). Connect w…

1
Episode 44. Maintenance Therapy in Multiple Myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin 52:58

2M ago52:58

52:58

In this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed: 1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation): https://pubmed.ncbi.nlm.nih.gov/28742454/ 2. My…

1
Primary CNS Lymphoma 1:09:06

3M ago1:09:06

1:09:06

CNS Lymphomas 1% of all NHL 3% of all Brain tumours Most common subtype (90%) is DLBCL Clinical division: 1. 1* CNS lymphoma, 2. 2* CNS lymphoma - TN-SCNSL - RI-SCNSL - RC-SCNSL 3. Immune deficiency assoc- HIV; better prog. Presentation: - SOL Sx - Raised ICP: morning headaches w N+V - Neuropsych, Behavioural, Memory, Language - Focal motor + Strok…

1
On the Shoulders of Giants is a hit (!) and I’m Fine is back 38:37

3M ago38:37

38:37

Hear about the premiere of the On the Shoulders of Giants film from HFA Symposium with Patrick and Amy. Plus the I’m Fine segment is back with Luke Pembroke and Hazri Aris is featured on the latest Elite Athletes segment. Show Notes: Subscribe: The BloodStream Podcast Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more. On the Sho…

1
Episode 43. Essential Thrombocythemia with Dr. Raajit Rampal 35:28

3M ago35:28

35:28

In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes: 1. IPSET (revised) system, risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status: · Very low risk: No prior thrombosis, age ≤60 years, JAK2-unmutated · Low risk: No prior th…

1
Chronic Monomyelocytic Leukemia (CMML) 41:56

4M ago41:56

41:56

Chronic MyeloMonocytic Leukemia (not CML) Persistently high monocyte count- 3 months Most frequent MDS/Myeloproliferative neoplasms – a cross between the two Median age 72 Median survival 20-40 months Transformation to AML (15-30%) WHO definition of CMML: 1. Excess monocytes- persistent over 3 months, ≥ 1 - Monocytes 10% of total WC count 2. Dyspla…

1
New NBDF CEO, Phil Gattone 38:55

3M ago38:55

38:55

We have newly appointed NBDF CEO, Phil Gattone with us sharing his background and his vision for the organization and community. And, we have the story of the first commercially dosed patient of hemophilia B gene therapy. Hear from Jamison Buxton, the father of the patient…who also happens to be the director of the HTC. Show Notes: Subscribe: The B…

1
Chronic Lymphocytic Leukemia (CLL) 1:18:33

4M ago1:18:33

1:18:33

Chronic Lymphocytic Leukemia (CLL)- Chronic Relapsing Remitting Most common leukemia in adults Incurable but treatable *Remember Supportive Care* Median age of 72 M > F 80% incidental SLL: lymphocytes in lymph nodes and spleen instead of blood Presentation: 1) Fatigue 2) B symptoms 3) High WC 4) Cytopenias (Marrow infiltrate, AIHA, ITP, Hyposplenis…

1
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer 48:15

4M ago48:15

48:15

In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: Rationale for targeting PARP in prostate cancer with ARI combinations Study design nuances and findings from key randomiz…

1
Episode 42. CAR T-cell Therapy in Early Relapsed Myeloma with Dr. Samer Al Hadidi 54:49

4M ago54:49

54:49

In this episode, we talked about overall survival data from CARTITUDE-4 and KarMMa-3 that was presented at FDA ODAC meeting with Dr. Samer Al Hadidi from University of Arkansas Myeloma Center. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma: a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/ b) CARTITUDE-4 (cilta-ce…

1
Dr. Glenn Pierce on the upcoming WFH Congress + CEO of Plasma Protein Therapeutics Association, Anita Brikman 45:09

4M ago45:09

45:09

Dr. Glenn Pierce is with us to share what to expect from the upcoming WFH Congress in Madrid, and Amy sits down with President and CCEO of the Plasma Protein Therapeutics Association (PPTA), Anita Brikman. FLOW co-host Jessica Richmond sits in for Patrick and we’ll finish up with an Elite Athletes segments will feature bleeding disorder community m…

1
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer 36:29

4M ago36:29

36:29

In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including: Challenges with the pathologic testing for HER2-low expression Optimal treatmen…

1
Episode 41. Career Development as a Clinician-Investigator with Dr. Ayalew Tefferi 47:22

4M ago47:22

47:22

In this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic.By Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

1
Highlights from ASH with Dr. Akshat Jain 44:04

4M ago44:04

44:04

We’re back with Dr. Akshat Jain who shares highlights in bleeding disorder research from ASH 2023, plus the differences between hemophilia A vs hemophilia B gene therapies with Dr. Mark Redding. We close out with our latest Elite Athletes segments featuring bleeding disorder community legend, Perry Parker. Don’t miss it! Show Notes: Subscribe: The …

1
What We’ve Learned So Far About Polycythemia Vera 35:56

5M ago35:56

35:56

On this episode, we travel back to our previous episodes to deliver some highlights of what we’ve learned so far. Dr. Prithviraj Bose gives us an overview of polycythemia vera, patient Nick Napolitano discusses his diagnosis, husband and wife team Joe and Patty Monteleone discuss the caregiver/patient relationship, David Wallace talks about his ins…

1
HFA CEO Dan Kelsey and Rare Disease Day tribute 1:08:50

5M ago1:08:50

1:08:50

HFA CEO Dan Kelsey joins Patrick and Amy to respond to recent organizational changes, followed by Blood Brother, Carl Weixler, who shares a bit about HFA’s history, mission, and current state. Also, a tribute to Rare Disease Day, led by voices from BloodStream Media. Show Notes: Subscribe: The BloodStream Podcast Presenting Sponsor: Takeda, visit b…

1
Episode 40. Management of Newly Diagnosed AL Amyloidosis with Dr. Angela Dispenzieri 52:34

5M ago52:34

52:34

In this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic. Here are the key articles discussed: 1. Optimal use of tissue biopsy in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/28271734/ 2. Mayo 2004 staging: https://pubmed.ncbi.nlm.nih.gov/15365071/ 3. Mayo 2012 staging: https://…

1
NBDF welcomes new CEO; HFA responds 28:50

6M ago28:50

28:50

NBFD landed a new CEO, and HFA has responded to recent organizational changes; plus, we hear from Dr. Mark Reding and Dr. Steven Pipe about their excitement over gene therapy being added to the treatment landscape in hemophilia. We close with @theHemeNP, Maya Bloomberg talkin’ Rare Disease Day. Show Notes: Subscribe: The BloodStream Podcast Present…

1
Episode 39. ASH 2023 Leukemia and Myeloid Neoplasm Recap with Dr. Anand Patel 55:14

6M ago55:14

55:14

In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel. Here are the abstracts that were discussed: 1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitini…

1
Polycythemia Vera: Treatment Considerations with Dr. Aaron Gerds 21:01

6M ago21:01

21:01

On this episode, we hear from Aaron Gerds, MD of the Cleveland Clinic about what to expect when starting treatment for polycythemia vera. He talks about setting treatment goals, monitoring treatment progress, how to have an open conversation with your doctor, and more on this episode of the PV Pod. Transparency Statement: The PV Cancer Podcast is p…

1
Preserving Tainted Blood History and Bath Bleeds 49:35

6M ago49:35

49:35

We’ve got a terrific interview with Kathy MacKay and Dana Kuhn about the efforts the Committee of Ten Thousand (COTT) is taking to preserve documents from the tainted blood tragedy. And another Elite Athletes segment featuring blood brother and cyclist, Giovanny Pernudi. Oh …and Patrick had a bath bleed. Show Notes: Subscribe: The BloodStream Podca…

1
Episode 38. GVHD Prophylaxis in Allo-Transplant with Dr. Shernan Holtan 52:10

6M ago52:10

52:10

In this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan from the University of Minnesota. Here are the key trials we discussed: 1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate,…

1
Shakeup at HFA and a brand new Gene Therapy segment! 45:27

6M ago45:27

45:27

It’s a New Year and BloodStream is back with a terrific episode. Major changes at @HFA leave Patrick wondering about the future of one of our beloved national organizations and we have folks from the FAIR initiative and CHES to share their 2024 vision for the women in bleeding disorders movement (heck yeah!). Plus, a brand new segment this year on …

1
SNL screws up sickle cell. 40:35

6M ago40:35

40:35

We’ve got SNL screwups, the mainstream acronyms continue to butcher rare blood diseases. Plus, we’ve got a new ELITE ATHLETES segment with Anthony Pezzillo (who recently became an uncle; or expanded his uncledom) and I’m Fine, this time with a focus on the caregiver experience with Jessica Bombardier. We’ll get into it all, AND MORE, on this episod…

1
Episode 37. ASH 2023 Myeloma Recap with Dr. Ben Derman 1:01:40

7M ago1:01:40

1:01:40

In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode: First, we will focus on a few abstracts in precursor states, MGUS. 1. New diagnostic criteria for light chain MGUS (IStopMM): https://ash.confex.com/ash/2023/webprogram/Paper…

1
Current Considerations for Adverse Event Management With HER3-Directed Agents 12:33

7M ago12:33

12:33

The third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of M…

1
Unpacking the Potential of HER3-Targeted Therapy in NSCLC 15:24

7M ago15:24

15:24

This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including: Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab The HER2xHER3 bispecific antibody zenocutuzumab The HER3-targeted anti…

1
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer 8:54

7M ago8:54

8:54

This first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD A…

Podcasts Worth a Listen

Polycythemia Vera Podcasts

Podcasts Worth a Listen

Quick Reference Guide